Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday. According to Zacks, “Jazz’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. However, Xyrem is facing patent challenges. Jazz has also been facing challenges […]
